Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.17 -0.33 (-0.21%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
From Beasley Allen Law Firm
Via Business Wire
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
From Ad Hoc Group of Counsel
Via Business Wire
3 Stocks Reeling From Ruined Reputations: Can They Recover?
Unforced errors by each of these controversial stocks has sullied their reputations and recovering them will not be easy or cheap. 
Via InvestorPlace
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
3 Beaten-Down Value Stocks Poised for a Massive Comeback: July 2024
Investors might want to consider these beaten-down value stocks, each of which looks poised for a turnaround in the year's second half. 
Via InvestorPlace
Check Out What Whales Are Doing With JNJ
Via Benzinga
Why the dividend investor may take a look at NYSE:JNJ.
Uncovering Dividend Opportunities with JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Via Benzinga
Exposures Product Safety
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his record and support Medicare for All. 
Via Benzinga
Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growing 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
From Beasley Allen Law Firm
Via Business Wire
Four Stocks To Watch This Week - Monday, July 22
It's possible that following the Crowdstrike/Microsoft outage last week, big investor over-reliance on the tech mega-caps could be under review in the medium term. 
Via Talk Markets
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epilepsy after Phase 2 data. 
Via Benzinga
Johnson & Johnson Faces Legal Hurdle In Talc Lawsuit Battle
Johnson & Johnson's attempt to disqualify Beasley Allen from representing plaintiffs in talc cancer cases is denied by a New Jersey judge, impacting the company's strategy to settle claims through... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Stocks See Mixed Reactions Amid Geopolitical Tensions And Earnings Surprises
Concerns were exacerbated by comments from former President Trump, raising fears of geopolitical tensions. 
Via Talk Markets
Topics Government
Exposures Political
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
This fund has a basket of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
MarketBeat Week in Review – 7/15 - 7/19
Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next 
Via MarketBeat
Topics Economy
Exposures Interest Rates
7 Consumer Staples Stocks to Buy at a 52-Week Low in July
If the long-awaited sector rotation is happening, it’s time to look at these undervalued consumer staples stocks. 
Via InvestorPlace
3 Blue-Chip Stocks to Buy for Christmas in July
Investors may be starting to rotate away from the tech sector, if so here are three blue-chip stocks to buy. 
Via InvestorPlace
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth. 
Via Benzinga
3 Dividend Stocks That Demand Investor Attention
Explore and consider three heavyweight dividend stocks that offer strong yields and growth potential for savvy investors. 
Via InvestorPlace
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Via Benzinga
3 Blue-Chip Stocks to Buy If the Dow Crashes
Blue-chip stocks provide the ballast to keep a portfolio steady when markets go south as they offer reliable long-term returns. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Microsoft To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
A Top-Tier Dividend Stock Every Passive-Income Investor Should Consider
This healthcare behemoth is one of the best dividend stocks on the planet. 
Via The Motley Fool
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly repo 
Via Benzinga
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.